Drug Trial Radar · NCT06564467
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202
Last checked: Nov 19, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
54
Planned (sponsor's estimate)
Start
Jul 23, 2024
Primary completion
Jan 10, 2025
Study completion Jul 10, 2025
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JMT202 in Healthy Participants.
Conditions
- Healthy Subjects
Interventions
JMT202Drug
subcutaneous injection
PlacrboDrug
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of adverse events (AEs) electrocardiogramsTime frame: Pre-dose and multiple timepoints no less than 50 days
- Number of participants with clinically significant change from baseline in vital signsTime frame: Pre-dose and multiple timepoints no less than 50 days
- Number of participants with clinically significant change from baseline in electrocardiogram (ECG) findingsTime frame: Pre-dose and multiple timepoints no less than 50 days
- Number of participants with clinically significant abnormalities in physical examinationTime frame: Pre-dose and multiple timepoints no less than 50 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.